Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 11/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 10/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807489 | 0.88 | SLC2A1 (0.52) | SLC2A1DRD3HTR2CDRD2DRD4 | |
| SCHEMBL6805196 | 0.76 | SLC2A1 (0.55) | SLC2A1DRD3HTR2CDRD2DRD4 | |
| SCHEMBL3106225 | 0.73 | SLC2A1 (0.60) | SLC2A1DRD3HTR2CDRD2DRD4 | |
| SCHEMBL6802923 | 0.73 | SLC2A1 (0.48) | SLC2A1DRD3CACNA1GDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL6712354 | 0.73 | SLC2A1 (0.59) | SLC2A1DRD3HTR2CDRD2DRD4 | |
| SCHEMBL6802847 | 0.72 | CCR3 (0.47) | DRD3DRD2DRD4 | |
| SCHEMBL6807063 | 0.72 | SLC2A1 (0.48) | SLC2A1DRD3DRD2DRD4DRD1 | |
| SCHEMBL3104995 | 0.68 | SLC2A1 (0.70) | SLC2A1 | |
| SCHEMBL3123342 | 0.66 | SLC2A1 (0.50) | SLC2A1DRD3CACNA1GDRD2DRD4 | |
| SCHEMBL3121723 | 0.65 | DRD2 (0.51) | SLC2A1DRD3DRD2DRD4DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | claimed |
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | SLC2A1 345/4885DRD3 222/4885CACNA1G 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.